IO Biotech Inc
IOBT0.843USD
-0.047-5.25%
Horário de mercado （ET）Cotações atrasadas em 15 min
55.54MValor de mercado
PerdaP/L TTM
Mais detalhes de IO Biotech Inc Empresa
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Informações de IO Biotech Inc
Código da empresaIOBT
Nome da EmpresaIO Biotech Inc
Data de listagemNov 05, 2021
CEODr. Mai-Britt Zocca, Ph.D.
Número de funcionários80
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 05
EndereçoOle Maaloes Veh 3
CidadeCOPENHAGEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísDenmark
Código postal2200
Telefone4570702980
Sitehttps://www.iobiotech.com/
Código da empresaIOBT
Data de listagemNov 05, 2021
CEODr. Mai-Britt Zocca, Ph.D.
Executivos da empresa IO Biotech Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Dr. Faical Miyara, Ph.D.
Dr. Faical Miyara, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
3.81%
Outro
49.30%
Investidores
Investidores
Proporção
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
3.81%
Outro
49.30%
Tipos de investidores
Investidores
Proporção
Venture Capital
46.07%
Investment Advisor
7.71%
Hedge Fund
4.10%
Investment Advisor/Hedge Fund
3.46%
Research Firm
2.49%
Individual Investor
0.34%
Outro
35.83%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
2023Q2
46
22.57M
78.34%
-5.75M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lundbeckfond Ventures
13.95M
21.18%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
10.35%
--
--
Apr 11, 2025
Vivo Capital, LLC
6.17M
9.37%
--
--
Jun 30, 2025
HBM Partners AG
3.94M
5.99%
--
--
Apr 11, 2025
Novo Holdings A/S
2.51M
3.81%
-842.00K
-25.10%
Aug 11, 2025
Marshall Wace LLP
2.11M
3.2%
--
--
Jun 30, 2025
PFM Health Sciences, LP
1.97M
2.99%
-369.03K
-15.76%
Jun 30, 2025
BofA Global Research (US)
1.62M
2.45%
-36.44K
-2.21%
Jun 30, 2025
Pivotal Bioventure Partners Investment Advisor LLC
864.20K
1.31%
--
--
Jun 30, 2025
Morgan Stanley Smith Barney LLC
653.68K
0.99%
-135.78K
-17.20%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
